Pharmapack Moves to May 2021

New date combines a Paris spring with the highest value pharma packaging event

Paris, 30 July 2020: Pharmapack Europe (#pharmapackeu), organised by Informa Markets, moves to May 2021 (19-20) to provide attendees, exhibitors and the pharma packaging community the best season and format. The decision follows a careful review with key stakeholders, with the exhibition continuing at its usual location: Hall 7.2 at Paris Expo, Porte de Versailles. More>>

Datwyler launches the Design Your Seal app

Datwyler is pleased to announce the launch of the Design Your Seal app. You can mix and match colors, personalize the aluminum seal and plastic disc, and explore a variety of options to meet your product and branding needs. Launch Design Your Seal app Once the designs are complete, the physical samples are assembled and shipped to the customer for evaluation. Design Your Seal helps to bridge the gap between Datwyler’s design process and the customer’s brand needs. More>>

CPhI Japan rescheduled for Spring 2021 with digital solutions to be launched

2021 postponement will ensure positive business conditions and greater attendance

Amsterdam, 27 July 2020: CPhI Japan – organised by Informa Markets – announces that, following a detailed review with partners and key industry stakeholders and to ensure the health and safety of our community, the event will be postponed until April 14-16, 2021. More>>

Healthcare Best-in-class syringe components for high safety and functionality

We are pleased to announce that Datwyler has become a strategic partner for the supply of the rubber plungers for the Retrago syringes. This is the result of intensive team work to develop the customized design of four different plungers, provide samples for trials and prepare commercial production within shortest time lines possible.   More>>

Vetter further expands its Development Service with new site in Austria

CDMO addressing growing customer demand Investment in additional clinical filling options in Europe Planned ‘go live’ in 2021 Ravensburg, Germany and Rankweil, Austria, July 8, 2020 – With biopharmaceutical development heavily focused on specialized therapeutics, drug sponsors are increasingly turning to expert outsourcing partners to meet growing demand for complex fill and finish solutions. Vetter, a leading global Contract Development and Manufacturing Organization (CDMO) is further investing in additional capacity to meet that growing global demand with the purchase of a clinical manufacturing site located in Austria. More>>

ERT Expands eCOA Solution for Higher Fidelity CNS Assessments

Partnership with Cogstate delivers digital cognitive assessments to improve the speed and effectiveness of clinical trials

ERT, the global leader in clinical endpoint data collection, today announced a preferred partnership with the leading neuroscience technology company, Cogstate, Ltd. The collaboration enables ERT to expand its industry-leading electronic Clinical Outcome Assessment (eCOA) solution with digital cognitive endpoint measurement to improve safety and efficacy assessment in clinical trials, including capabilities for at-home testing. More>>

Cognizant Shared Investigator Platform for Life Sciences Reaches Major Milestone in Accelerating Drug Discovery

More than 100,000 Life Sciences Researchers, Clinicians and Professionals in 84 Countries Utilizing Innovative SaaS Solution to Help Speed New Drug Therapies to Market

Cognizant (Nasdaq: CTSH) announced that its Shared Investigator Platform (SIP), a life sciences Software as a Service (SaaS) solution, has reached a new milestone of over 100,000 users in 84 countries. The platform has become increasingly critical to progressing clinical trials as prevailing social distancing norms have significantly curtailed in-person collaboration. More>>

Takeda Provides Updates on Its Pharmacokinetic-guided Prophylaxis Studies at ISTH 2020, Reinforcing Its Commitment to Advancing Personalized Care for People with Bleeding Disorders

July 12, 2020 - The Data Demonstrating Benefits of Pharmacokinetic-Guided Prophylaxis Therapy in Hemophilia and von Willebrand Disease are Among 13 Presentations from Takeda’s Hematology Portfolio and Pipeline More>>

Byondis’ Investigational Antibody-Drug Conjugate SYD985 Selected for I-SPY 2 TRIAL™ in Early-Stage Breast Cancer

New Treatment Arm with [vic-]trastuzumab duocarmazine Will Focus on HER2-Low Early-Stage, High-Risk Breast Cancer

Byondis B.V. (formerly Synthon Biopharmaceuticals) today announced that Quantum Leap Healthcare Collaborative™ (Quantum Leap) selected the company’s investigational antibody-drug conjugate (ADC) SYD985 ([vic-]trastuzumab duocarmazine) for a new investigational treatment arm in its ongoing I-SPY 2 TRIAL™ for neoadjuvant treatment of locally advanced breast cancer. More>>

Engineered llama antibodies neutralise Covid-19 virus

The Rosalind Franklin Institute has been developing nanobodies from llamas to combat COVID-19

Researchers have developed a family of engineered nanobodies which neutralise the SARS-CoV-2 virus, targeting the viral spike protein in a novel way. More>>